Summary. Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase for the management of hyperuricemia in patients with gout. The ability of febuxostat to decrease serum uric acid ...

Febuxostat is a second-line option for patients with gout who are unable to take allopurinol due to hypersensitivity, intolerance, or lack of efficacy in achieving a target serum uric acid ...

Nephrologist Jason B. Rothschild, MD, recently joined Gayle Guyardo, the host of the globally syndicated health and wellness show Bloom, to discuss the often-overlooked ...

Uric acid crystals can accumulate under the skin and form lumps called "tophi." Chronic (long-term) gout can cause knee ...

The third phase, inter-critical gout, is a period between acute attacks when the patient is symptom-free. Finally, chronic ...

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to ...

Arthrosi Therapeutics doses first patient in replicate pivotal phase 3 REDUCE 1 trial of lead compound AR882: San Diego Wednesday, March 19, 2025, 11:00 Hrs [IST] Arthrosi Therape ...